Author + information
- Received May 29, 2007
- Revision received October 5, 2007
- Accepted November 8, 2007
- Published online March 11, 2008.
- Chiara Melloni, MD, MHS⁎,
- Eric D. Peterson, MD, MPH⁎,
- Anita Y. Chen, MS⁎,
- Lynda A. Szczech, MD, MSCE⁎,
- L. Kristin Newby, MD, MHS⁎,
- Robert A. Harrington, MD⁎,
- W. Brian Gibler, MD†,
- E. Magnus Ohman, MD⁎,
- Sarah A. Spinler, PharmD, FCCP‡,
- Matthew T. Roe, MD, MHS⁎ and
- Karen P. Alexander, MD⁎,⁎ ()
- ↵⁎Reprint requests and correspondence:
Dr. Karen P. Alexander, 2400 Pratt Street, Duke Clinical Research Institute, Durham, North Carolina 27705.
Objectives Our purpose was to compare formulae for estimating glomerular filtration rate (GFR) in non–ST-segment elevation acute coronary syndromes (NSTE ACS) patients.
Background Assessment of GFR is important for antithrombotic dose adjustment in NSTE ACS patients.
Methods We assessed estimated glomerular filtration rate (eGFR) with Cockcroft-Gault (C-G) and Modification of Diet in Renal Disease (MDRD) formulae in 46,942 NSTE ACS patients from 408 CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines) hospitals. Formula agreement was shown continuously and by chronic kidney disease (CKD) stages. We determined in-hospital outcomes and the association between antithrombotic dose adjustment and bleeding for moderate CKD as determined by each formula.
Results The median (interquartile range [IQR]) eGFR was 53.2 ml/min (34.7, 75.1 ml/min) by C-G and 65.8 ml/min (47.6, 83.5 ml/min) by MDRD. The mean eGFR was higher with MDRD (∼9.1 ml/min), but this difference was greater in age, weight, and gender subgroups. Chronic kidney disease classification differed in 20% of the population and altered when antithrombotic dose adjustment was required by C-G versus MDRD (eptifibatide: 45.7% vs. 27.3%; enoxaparin: 19.0% vs. 9.6%).
Conclusions Important CKD disagreements occur in ∼20% of acute coronary syndrome patients, affecting dosing adjustments in those already susceptible to bleeding. Dosing based on C-G formula is preferable, particularly in the small, female, or elderly patient.
The CRUSADE initiative is a National Quality Improvement Initiative of the Duke Clinical Research Institute. The CRUSADE initiative is funded by the Schering-Plough Corporation. The Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership provides additional funding support. Millennium Pharmaceuticals, Inc., funded part of this work. This work is also supported, in part, by a grant from the National Institute on Aging (R01 AG025312-01A1, PI Peterson). More information on CRUSADE can be found at http://www.crusadeqi.com.
- Received May 29, 2007.
- Revision received October 5, 2007.
- Accepted November 8, 2007.
- American College of Cardiology Foundation